WO1995004830A1 - Mycoplasma expression system - Google Patents
Mycoplasma expression system Download PDFInfo
- Publication number
- WO1995004830A1 WO1995004830A1 PCT/US1993/007407 US9307407W WO9504830A1 WO 1995004830 A1 WO1995004830 A1 WO 1995004830A1 US 9307407 W US9307407 W US 9307407W WO 9504830 A1 WO9504830 A1 WO 9504830A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mycoplasma
- promoter
- regulatory
- lacz
- acholeplaεma
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
Definitions
- mycoplasmas a group of organisms collectively known as "mycoplasmas," many of which are important human and agricultural pathogens. Despite this pathogenicity, little is known about the genetics of mycoplasmas. These organisms possess the smallest genome thought necessary for autonomous existence. Razin, Microbiol . Rev. 49: 419-55 (1985). Due to their simplicity, most mycoplasma species require complex media for growth because they lack many biosynthetic pathways. In view of such limitations, traditional genetic studies employing auxotrophic mutants have not been possible with these organisms.
- mycoplasmas are thought to be a product of degenerative evolution from Gram-positive organisms.
- Previous studies of 16S rRNA sequence homology have suggested that mycoplasmas are more closely related to Gram-positive organisms than Gram-negative organisms eisburg et al . , J. Bacteriol . 171: 6455-67 (1989).
- the differences in translational specificity that have been demonstrated between the Gram-negative and Gram-positive bacteria also appear to pertain to mycoplasmas as well.
- Hager & Rabinowitz The Molecular Biology of the Bacilli 1-34 (Dubnau ed., Acad. Press 1985).
- the simplicity of mycoplasmas offers advantages in the context of expression systems.
- mycoplasmas lack lipopolysaccharide and other toxic wall constituents, which would allow for simplified purification of recombinantly produced proteins.
- Significant problems have existed, however, with using mycoplasmas as a recombinant expression system. Adequate stability of cloned genes has previously not been achieved.
- previous attempts at creating mycoplasma-based expression systems have employed gram-negative promoters, which was necessitated by the unavailability and limited knowledge regarding mycoplasma promoters, generally. The transcriptional apparatus of gram-negative bacteria, however, is often unable to correctly recognize mycoplasma promoter sequences.
- Dybvig & Alderete Pla ⁇ mid 20: 33-41 (1988); Dybvig & Cassell, Science 235: 1392-94 (1987); Mahairas & Minion, Plasmid 21: 43-47 (1989) .
- a number of broad host-range plasmids from Gram-positive bacteria have been examined as possible cloning vectors, but all have proven to be unstable.
- Naturally occurring mycoplasma plasmids have also been examined as possible cloning vectors, but they have not been shown to maintain and express a cloned gene.
- It still another object of the present invention to provide a plasmid comprising mycoplasma regulatory sequences and a site for inserting foreign DNA. It is yet another object of the present invention to provide a plasmid where the mycoplasma regulatory sequences control the expression of the foreign DNA.
- an expression system employing mycoplasma regulatory sequences to control the expression of foreign DNA in host cells.
- Suitable host cells include the members of the class Mollicute ⁇ , such as Acholepla ⁇ ma .
- a plasmid comprising a mycoplasma promoter sequence and foreign DNA, which is transformed into an appropriate host in order to produce the protein encoded by the foreign DNA.
- the plasmid may further comprise mycoplasma DNA that is normally located upstream of a mycoplasma promoter in the native environment.
- the foreign DNA may include mycoplasma DNA.
- the mycoplasma regulatory sequences may be from Acholepla ⁇ ma or other mycoplasma genre.
- the expression system can the include -* or more complete mycoplasma regulatory region or one c aore fragments thereof. Additionally, the expression vector of the present invention can include more than one mycoplasma regulatory sequence, or combinations of mycoplasma sequences or fragments thereof.
- FIGURE 1 is a chart of the major strains and plasmids employed to develop the present invention.
- Genotypes/phenotypes of Acholepla ⁇ ma transformants are defined by the nomenclature of "original strain: :plasmid.”
- FIGURE 2 depicts the construction of trp'-lacZYA fusion plasmids 2004, 2005, 2006, 2009, 2010 and 2011.
- Single headed arrows indicate the direction of transcription.
- the double headed arrow and the hatched bar denote the 700 bp region found upstream of the M. capricolum rrn P2 promoter.
- ⁇ f. cap. refers to M. capricolum
- Amicillin resistance refers to ampicillin resistance
- Gm refers to gentamicin resistance
- u ori refers to origin of replication.
- This figure also sets forth ⁇ -galactosidase activity for E. coli CSH50 and Acholepla ⁇ ma ISM1520 strains transformed with each plasmid.
- FIGURE 3 depicts the construction of the transcriptional fusion vector pISM2050.
- the vector was constructed by ligating a 3.1 kb BaraHI DNA fragment containing the promoterless lacZ from plasmid pMC1871 into the BamHI site of plasmid pISM1003.
- the arrow indicates the direction of transcription of lacZ .
- the asterisk (*) indicates a BamEI site that was inactivated.
- Amin refers to a picillin resistance
- G refers to gentamicin resistance
- Tc refers to tetracycline resistance
- p- lacZ refers to promoterless lacZ
- ori refers to the origin of replication.
- FIGURE 4 depicts data from ⁇ -gal assays performed with seven of the lacZ fusion constructs introduced into ISM1520. CSH50 and ⁇ 289 served as controls.
- FIGURE 5 depicts the alignment and determination of putative -10 and -35 promoter regions driving lacZ in plasmid pISM2050 derivatives based on similarity a consensus E. coli promoter sequence. Bold letters indicate transcriptional start sites.
- Figure 6 depicts the sequence upstream (a region containing regulatory sequences) of the lacZ gene in fusion construct pISM2050.1. Additionally, the lacZ-chromosomal DNA fusion is shown in italics (GATC) . The putative -35 and -10 promoter regions are underlined and the transcriptional start site is indicated by an (*) . The potential ribosomal binding site (rbs) and translational start site (start) are also underlined. These designations are also employed in Figures 7-12. Figure 7 depicts the sequence upstream of the lacZ gene in fusion construct pISM2050.2.
- Figure 8 depicts the sequence upstream of the lacZ gene in fusion construct pISM2050.8.
- Figure 9 depicts the sequence upstream of the lacZ gene in fusion construct pISM2050.18.
- Figure 10 depicts the sequence upstream of the lacZ gene in fusion construct pISM2050.25.
- Figure 11 depicts the sequence upstream of the lacZ gene in fusion construct pISM2050.69.
- Figure 12 depicts the sequence upstream of the lacZ gene in fusion construct pISM2050.70. A potential ribosomal binding site (“rbs”) was not found.
- a lack of specific information concerning mycoplasma regulatory sequences and regions containing these sequences heretofore has combined with an inability to readily detect or identify mycoplasma promoters and other regulatory sequences by means of cloning into E. coli .
- a protein fusion construct wherein a putative mycoplasma regulatory region is tested for an ability to drive expression of a reporter gene, lacZ, can be employed advantageously in a mycoplasma, such as an Acholepla ⁇ ma host, thereby to confirm the existence of an actual regulatory sequence in the test region.
- regulatory sequence denotes any sequence that controls or affects the transcription of DNA into RNA or the translation of RNA into a protein.
- exemplary of such regulatory sequences are promoters, ribosome binding sites, and translation start sites.
- a "regulatory region” contains regulatory sequences. That the lacZ gene could fulfill such a reporter function in mycoplasma was not predictable in light of the uncertainty that generally surrounded heterologous expression in mycoplasma. Thus, there was little or no information previously available on whether mycoplasma tRNA concentration and availability could accommodate expression of an exogenous gene, on whether stability of foreign mRNA would be sufficient for such expression, or on whether an heterologous expression product, if obtained, would possess adequate stability in the mycoplasma host.
- an appropriate reporter gene with an upstream cloning site is useful for analysis of regulatory regions containing regulatory sequences of mycoplasmas.
- Use of an appropriate reporter gene can identify regulatory regions and assist in the analysis of defined mutations regulatory sequences. Accordingly, the present invention allows for the further identification and modification of mycoplasma regulatory sequences or regions containing these sequences.
- Another aspect of the present invention relates to purified mycoplasma regulatory sequences or regions for use in an expression vector.
- the term "purified” in the context of this invention refers to a degree of purity greater than that found in nature, preferably a degree of purity that is sufficient for purposes of constructing an expression vector.
- the regulatory sequences or regions of the invention may be obtained by means such as isolation from natural sources or chemical synthesis. Purified fragments and derivatives of mycoplasma regulatory regions and sequences found in nature are also within the scope of this invention.
- a further aspect of the present invention involves employing at least one mycoplasma regulatory sequence or region operably linked to foreign DNA in an expression vector. Because the regulatory sequence or region and foreign DNA are arranged in this manner, the regulatory sequence or region controls the expression of the foreign DNA when the vector is within a host, which preferably is a mycoplasma. Other appropriate hosts may be employed as well.
- the regulatory region, sequence, or fragments thereof may be combined when used in the expression system of the present invention. Cells transformed with these expression vectors are also within the scope of this invention.
- the term "foreign DNA” includes any DNA that encodes the desired product.
- the foreign DNA can be isolated from natural sources, can be generated from RNA via reverse transcription or can be synthesized. Natural sources include any entity that possesses DNA or RNA, including mycoplasmas.
- the present invention includes the use of a mycoplasma host, such as Acholepla ⁇ ma , transformed with a plasmid containing a mycoplasma regulatory sequence and a DNA sequence (that is, a foreign DNA) from a virus, bacterium, animal or plant.
- the foreign DNA can be from a mycoplasma, even from an Acholepla ⁇ ma.
- the foreign DNA encodes a protein.
- mycoplasma proteins will allow for the identification of mycoplasma antigens useful for creating vaccines. Additionally, the production of antigenic mycoplasma proteins permits the development antibodies directed against mycoplasma antigens. Such antibodies would have diagnostic and therapeutic uses.
- the foreign non-mycoplasmal proteins produced by the present invention are also useful, especially in the context of vaccine production and development of antibodies.
- E. coli lacZ as a reporter gene in mycoplasmas was evaluated by examining the ability of a known mycoplasma or E. coli promoter to generate ⁇ - galactosidase ( ⁇ -gal) activity from a transcriptional fusion with the trp'-lacZYA operon.
- Gene fusions have proven to be powerful tools for studying prokaryotic transcriptional and translational control elements. Silhavy & Beckwith, Microbiol . Rev. 49: 398-418 (1985); Silhavy et al . EXPERIMENTS WITH GENE FUSIONS, COLD SPRING HARBOR (1984); Simons, et al . , Gene 53: 85-96 (1987). This fusion employed E. coli translational start sites.
- Plasmids pISM2004-2006 and pISM2009-2011 were constructed and transformed into E. coli CSH50 and Acholeplasma ISM1520. See Figure 1.
- Acholepla ⁇ ma strain designations ISM2004-2010 represent recombinants containing plasmid pISM2004-pSM2010, respectively.
- E. coli Dfl5 ⁇ and ⁇ 289 were obtained from Bethesda Research Labs and R. Curtiss, respectively.
- Acholepla ⁇ ma ISM1499 was a laboratory isolate.
- Acholepla ⁇ ma ISM1520 was constructed by transformation of ISM1499 with the plasmid pISM1026 Tc r .
- Plasmid pISM1026 Tc r is a derivative of cloning vector pSP64 (Promega) , and contains the tetracycline resistance marker from TN916 and an approximately 5kb fragment of Acholepla ⁇ ma DNA (for insertion into the chromosome) .
- Plasmid pDIA15 is disclosed in De Reuse et al . , FEMS Micro . Lett . 37: 193-97 (1986).
- Plasmid pMC187l is disclosed in Casadaban et al . , Meth . Enzymol . 100:293-308 (1983).
- Plasmid pISM1003 is disclosed in Mahairas et al .
- Plasmids pISM2005 and pISM2006 were constructed by inserting the 7.1 kb BamHI fragment containing trp'-lacZYA from plasmid pDIA15 (De Reuse, et al . , FEMS Micro . Lett . 37: 193-97 (1986)) downstream of the promoters in plasmids pISM2002 and pISM2003. See Figure 2.
- Plasmids pISM2010 and pISM2009 are identical to plasmids pISM2005 and PISM2006, respectively, except that an additional 700 bp region upstream of the M. capricolum rrnB P2 promoter has been placed upstream of the promoters in the plasmids.
- Plasmid pISM2011 is identical to plasmid pISM2010 except that the M. capricolum promoter and rrnB P2 upstream sequences are in the reverse orientation.
- Acholepla ⁇ ma cells were grown in PPLO broth (Difco Laboratories, Detroit, Mich.) supplemented with 15% gamma globulin-free horse serum (GIBCO Laboratories, Grand Island, N.Y.), 2.5% yeast extract, 0.5% glucose, 2.5 mg/ml of Cefobid (Pfizer, Inc., New York, N.Y.), 0.02% (wt/vol) DNA (Sigma Chemical Co., St.
- ⁇ - galactosidase assays were performed as described by Schleif & Wensink, PRACTICAL METHODS IN MOLECULAR BIOLOGY (Springer-Verlag 1981) .
- Z buffer 0.1 M sodium phosphate, pH 7.0; 0.001 M magnesium sulfate; 0.1 M 2-mercaptoethanol.
- Fifty microliters of 0.1% SDS was added to l ml of the cell suspension and vortexed for 15 seconds.
- the M. capricolum promoter was able to drive the expression of lacZ in both E. coli and Acholepla ⁇ ma ISM1520, but the overall levels of ⁇ -gal activity in Acholepla ⁇ ma were low in comparison to levels in E. coli . Slightly higher levels of ⁇ -gal activity were generated in Acholepla ⁇ ma with the additional 700 bp region from the M. capricolum rrnB Pl promoter region in plasmid pISM2010. This supported an earlier observation that the upstream region of the M. capricolum rrnB P2 promoter influences transcriptional levels. Josaitis et al . , Biochim . Biophys . Acta . 1050: 307-11 (1990). The M. capricolum promoter in the reverse orientation with respect to lacZ (pISM2011) was not able to generate ⁇ -gal activity in either Acholepla ⁇ ma or E. coli .
- RNA levels from Acholeplasma ISM1499, ISM1520, ISM2004, ISM2005, ISM2006, ISM2009, and ISM2010 were performed with either 16S rRNA, to standardize the assay, or a Iac2-specific probe. Counts per volume were detected by the PHOSPHORIMAGER (Molecular Dynamics, Sunnyvale, CA) and analyzed with the IMAGEQUANT program (Molecular Dynamics, Sunnyvale, CA) . All blots with the 16S rRNA probe showed hybridization.
- the values obtained with the lacZ probe in counts per minute after subtracting background and adjusting for amounts of RNA loaded are set forth in parenthesis following the identification of the transformant: ISM1499 (0), ISM1520 (0), ISM2004 (40,652), ISM2005 (543,651), ISM2006 (0), ISM2009 (32,574), ISM2010 (329,117) .
- the trp'-lacZ mRNA transcript levels in ISM2005 and ISM2010 were relatively high despite the low levels of ⁇ - gal being produced. Both of these transformants contain the M. capricolum rrnA P2 promoter. Surprisingly, the E. coli consensus promoter ⁇ E.
- Plasadaban et al . , supra The construction of plasmid pISM2050 is illustrated in Figure 3.
- the parent plasmid, pISM1003 was digested with BamHI and the 3.1 kb BamHI fragment of plasmid pMC1871 (Casadaban et al . , supra) containing a promoterless lacZ gene was ligated into the site.
- the downstream BamK site was removed by partial digestion with Bam ⁇ T followed by a fill- in reaction with Klenow fragment of DNA polymerase I, ligation to circularize, and transformation into E. coli .
- Transformants were selected on ampicillin containing media, and tne proper construct was confirmed by restriction enzyme analysis.
- Plasmid pISM2050 was constructed with a gentamicin marker for selection in mycoplasmas, a promoterless lacZ reporter gene with unique upstream Bat ⁇ HI and S al. restriction enzyme sites for cloning Sau3AI and blunt end fragments, respectively, and an ampicillin marker and origin of replication for amplification of DNA in E. coli prior to transformation into Acholeplasma . It should be noted, however, that when Sau3Al fragments are ligated into BamHI sites, the BamHI site is often lost.
- the ampicillin gene and origin of replication also provided a region of homology to insert the plasmid into the Acholeplasma recipient strain ISM1520 via homologous recombination. See Mahairas & Minion, J. Bacteriol . 171: 1775-80 (1989); Mahairas et al . , Gene 93: 61-66.
- a library of cloned fragments was produced and screened for ⁇ -galactosidase activity in E. coli prior to introduction into Acholeplasma because of the large quantity of plasmid DNA (7 to 10 ⁇ g) required for transformation into mycoplasmas.
- chromosomal DNA was prepared by washing the cells from a 500 ml culture with phosphate buffered saline (PBS, 10 mM sodium phosphate, 150 mM NaCl, pH 7.4) and re- suspending the pellet in 5 ml of NET buffer (0.1 M Tris, 0.15 M NaCl, and 0.08M EDTA, pH 7.5) containing 10 mg/ml Proteinase K. After 2 hours of incubation at 37°C, the cells were lysed with 1 ml of a detergent solution containing 1% sodium dodecyl sulfate (SDS) , 1% Nonidet P- 40, and 1% deoxycholate.
- PBS phosphate buffered saline
- NET buffer 0.1 M Tris, 0.15 M NaCl, and 0.08M EDTA, pH 7.5
- Plasmid DNA from five independent colonies were pooled together and used to transform Acholepla ⁇ ma ISM1520. If a mycoplasma transformant from the plasmid pool demonstrated ⁇ -gal activity based on blue colony formation on X-gal-containing media, each plasmid DNA from that pool was then used to transform Acholeplasma ISM1520.
- RNA STAT-60 isolation reagent Tel-Test "B", Inc., Friendswood, Tex.
- Messenger RNA levels were measured by slot blot analysis using a Minifold II apparatus (Schleicher & Schuell, Keene, N.H.) and following the procedure described in Sambrook, et al . MOLECULAR CLONING, A LABORATORY MANUAL, COLD SPRING HARBOR (1989) .
- RNA samples Two micrograms of total RNA were placed into each slot and transferred to nitrocellulose (Schleicher & Schuell) and probed with a 1.4 kb fragment containing the 16S rRNA gene from ISM1499 or a 3.1 kb fragment containing the lacZ gene.
- the blot was exposed to x-ray film or was examined with a PHOSPHORIMAGER and analyzed with the IMAGEQUANT program.
- Levels of the lacZ mRNA were adjusted by normalizing to the 16S rRNA levels to account for differences in amounts of RNA that may have been loaded in each slot for each strain. The results in figure 4 correlate with the ⁇ -gal assay results in that strains demonstrating higher transcript levels generally had higher levels of ⁇ -gal activity.
- Units of ⁇ -gal activity A 420 x 4.45 x 10 12 monomers time (min) x mg protein x CFU/mg
- Immunoblot analysis was performed with several recombinant Acholeplasma strains to demonstrate the production of a ⁇ -gal fusion protein.
- Protein samples containing 25 ⁇ g protein from washed mycoplasmas were re- suspended in water and lysed with 0.01% (final concentration) SDS, then SDS-PAGE sample buffer (Laemmli, Nature 227: 680-85 (1970) was added, and the samples were boiled for 5 minutes and then separated on a 7.5% polyacrylamide resolving gel. Following electrophoresis for 4 hours at 25 mAmp constant current, proteins were transferred to nitrocellulose following the procedure of Towbin, et al . , Proc . Nat 'l Acad . Sci .
- the blots were analyzed using a 1:3,000 dilution of a monoclonal antibody to ⁇ -gal (Promega) followed by goat anti-mouse antibody conjugated to alkaline phosphatase (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, Md.) (1:1,000 dilution).
- the blot was developed by using the BCIP/NBT one component alkaline phosphatase substrate system (Kirkegaard & Perry Laboratories, Inc.).
- Acholepla ⁇ ma ISM1520 strains with high levels of ⁇ -gal activity reacted more strongly with the anti- ⁇ -gal monoclonal antibody, which supports the results of the ⁇ - gal assay.
- EXAMPLE 3 DNA sequencing of promoter-containing DNA fragments
- the chromosomal DNA inserts adjacent to the lacZ gene in the pISM2050 derivatives were sequenced by using an oligonucleotide sequencing primer.
- This primer (5 / -GCTGGCGAAAGGGGGATG GCTGCAAGGCG-3 , ) is reverse and complimentary to the lacZ gene at approximately 50 nucleotides downstream of the lacZ-chromosomal DNA fusion point.
- Other sequencing primers such as the T7, T3 and Mi3 forward and reverse primers, were also employed in the sequencing of chromosomal inserts.
- the SEQUENASE kit United States Biochemical is suitable for this sequencing.
- the chromosomal inserts were sequenced by first subcloning the inserts into pSP71 (Promega Corp.) or isolating a Clal fragment containing the insert, the junction site and a portion of lacZ from an agarose gel and purification with GeneClean. The fragments were removed from pISM2050 for sequence analysis because pISM2050 was derived from pKS (Stratagene) , which also contains the portion of lacZ that is recognized by the sequencing primer.
- the transcriptional start sites for the promoters driving the expression of lacZ in the fusion plasmids pISM2050.1, pISM2050.2, pISM2050.8, pISM2050.18, pISM2050.25, pISM2050.69, and pISM2050.70 were mapped by primer extension method of Ausebel et al . , CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (John Wiley & Sons 1989) . See Figure 5. Three microliters of the primer extension product were electrophoresed on an 8% sequencing gel. The primer extension products were compared to a sequencing ladder generated by using pISM2083 with the sequencing primer. The difference in the distance from the lacZ- chromosomal DNA fusion point to the base corresponding to the primer extension product was then mapped on a previously determined sequence map for each plasmid.
- the transcriptional start sites and upstream regions of the lacZ fusion transcripts for seven of the ISM2050 derivatives are shown in Figure 5.
- the upstream regions were aligned to the putative sequences encompassing the -10 and -35 promoter regions.
- the regions were defined based on their similarity to the E. coli consensus promoter. Hawley and McClure, Nucl . Acid ⁇ Re ⁇ . 11: 2237-55 (1983).
- the spatial relationships between the transcriptional start and the -10 region as well as between the -10 region and the -35 region were similar to the E. coli consensus promoter.
- sequences upstream of the lacZ gene in pISM2050.1, pISM2050.2, pISM2050.8, pISM2050.18, pISM2050.25, pISM2050.69 and pISM2050.70 are set forth in Figures 6-12, respectively.
- the potential ribosomal binding sites for each sequence were determined by aligning the sequence with the last 15 bp at the 3' end of the 16S rRNA gene of A. laidlawii .
- a consensus promoter sequence for the seven pISM2050 fusion derivatives in the -10 and -35 regions were TATaW and TtcAtn, respectively.
- Upper case letters denote that at least 5 of the 7 pISM2050 derivatives contain the base.
- Lower case letters denote that at least 3 of the 7 pISM2050 derivatives contain the base in the designated position.
- W denotes A or T
- n denotes any base. See Figure 5.
- the average number of bases that align between the ISM1499 promoter regions and the E. coli consensus promoter regions are 4.4 bp for the -10 region and 3 bp for the -35 region.
- the 3 bp conservation at the -35 region is about 1 bp less than the 3.9 bp observed with the E. coli and phage promoters. See Figure 5.
- the observation that the - 10 region was more like the E. coli consensus promoter than the -35 region is consistent with previous reports examining the putative mycoplasma promoter regions.
- Figures 6-12 set forth sequence data from several mycoplasma regulatory regions, which contain regulatory sequences. These regulatory regions, or fragments of these regions, can be used to construct an expression vector suitable for expressing foreign DNA sequences (typically genes) in mycoplasmas, such as Acholepla ⁇ ma .
- An expression vector within this invention could include the entirety of one of the mycoplasma regulatory regions identified in Figures 6-12, or one or more fragments thereof.
- the expression vector of the present invention can include more than one mycoplasma regulatory region or sequence.
- the expression system can include combinations of mycoplasma regions, sequences or fragments thereof.
- the expression vector pISM303 was constructed as follows. Primers PK101910 - 5' GACGGGATCCTTAAATACTAA 3' and PK101912 - 5' CGTAAGCTTCCTCCAACAACAAAAACCTTGA 3' were constructed to obtain the mycoplasma regulatory region contained in pISM2050.2. Primer PK101910 creates a BaroHI site and primer PK101912 creates a Hindlll site, both of which are underlined in the above sequences.
- a promoterless tet ⁇ gene was constructed by PCR and inserted into the unique BamHI site of pISM303. Plasmids with the proper tetM orientation confirmed by restriction analysis were transformed into E. coli or Acholepla ⁇ ma ISM1503. Acholeplasma ISM1503 was obtained by transforming strain ISM1499 with pISM1007. This integrative plasmid is a pKS derivative that encodes the gentamicin resistance marker from TN4O02. See Mahairas & Minion, J. Bacteriol . 171:1775-80 (1989). Other bacterial and mycoplasmal recipient strains are suitable for use with the present invention as well.
- Plasmid pISM303 integrates into the genome of Acholeplasma ISM1503 by homologous recombination between the common ampicillin resistance marker sequences. Other regions can be employed as well, as long as the expression vector and the recipient strain possess a homologous region.
- E. coli and Acholeplasma transformants were identified by tetracycline resistance arising from expression of tetM controlled by the mycoplasmal regulatory sequence in pISM303, thereby further demonstrating the usefulness of the present invention.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93918682A EP0715654A1 (en) | 1993-08-06 | 1993-08-06 | Mycoplasma expression system |
AU48042/93A AU4804293A (en) | 1993-08-06 | 1993-08-06 | Mycoplasma expression system |
PCT/US1993/007407 WO1995004830A1 (en) | 1993-08-06 | 1993-08-06 | Mycoplasma expression system |
US08/592,406 US5821059A (en) | 1993-08-06 | 1993-08-06 | Mycoplasma expression system |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1993/007407 WO1995004830A1 (en) | 1993-08-06 | 1993-08-06 | Mycoplasma expression system |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995004830A1 true WO1995004830A1 (en) | 1995-02-16 |
Family
ID=22236829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/007407 WO1995004830A1 (en) | 1993-08-06 | 1993-08-06 | Mycoplasma expression system |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0715654A1 (en) |
AU (1) | AU4804293A (en) |
WO (1) | WO1995004830A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1373885A2 (en) * | 2001-03-29 | 2004-01-02 | Evogene Ltd. | Methods, platforms and kits useful for identifying, isolating and utilizing nucleotide sequences which regulate gene expression in an organism |
US7695968B2 (en) | 2003-03-12 | 2010-04-13 | Evogene Ltd. | Nucleotide sequences regulating gene expression and constructs and methods utilizing same |
-
1993
- 1993-08-06 EP EP93918682A patent/EP0715654A1/en not_active Withdrawn
- 1993-08-06 AU AU48042/93A patent/AU4804293A/en not_active Abandoned
- 1993-08-06 WO PCT/US1993/007407 patent/WO1995004830A1/en not_active Application Discontinuation
Non-Patent Citations (5)
Title |
---|
GENE, Vol. 93, issued 1990, GREGORY G. MAHAIRAS et al.: "Development of a cloning system in Mycoplasma pulmonis", pages 61-66, see entire article. * |
NUCLEIC ACIDS RESEARCH, Vol. 16, No. 1, issued January 1988, R. GAFNY et al.: "Promoters of Mycoplasma capricolum ribosomal RNA operons: identical activities but different regulation in homologous and heterologous cells", pages 61-76, see entire article. * |
PLASMID, Vol. 21, issued 1989, GREGORY G. MAHAIRAS et al.: "Random insertion of the Gentamicin Resistance transposon tn4001 in Mycoplasma pulmonis", pages 43-47, see entire article. * |
PLASMID, Vol. 21, issued 1989, KEVIN DYBVIG: "Transformation of Acholeplasma laidlawii with Streptococcal plasmids pVA868 and pVA920", pages 155-160, see entire article. * |
R. RODRIQUEZ et al., "Vectors", published 1988 by BUTTERWORTHS (BOSTON), see pages 153-177, see entire document. * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1373885A2 (en) * | 2001-03-29 | 2004-01-02 | Evogene Ltd. | Methods, platforms and kits useful for identifying, isolating and utilizing nucleotide sequences which regulate gene expression in an organism |
EP1373885A4 (en) * | 2001-03-29 | 2004-06-23 | Evogene Ltd | Methods, platforms and kits useful for identifying, isolating and utilizing nucleotide sequences which regulate gene expression in an organism |
US7695968B2 (en) | 2003-03-12 | 2010-04-13 | Evogene Ltd. | Nucleotide sequences regulating gene expression and constructs and methods utilizing same |
Also Published As
Publication number | Publication date |
---|---|
EP0715654A1 (en) | 1996-06-12 |
AU4804293A (en) | 1995-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dammel et al. | Suppression of a cold-sensitive mutation in 16S rRNA by overexpression of a novel ribosome-binding factor, RbfA. | |
Cox et al. | The mechanism of ATP synthase: a reassessment of the functions of the b and a subunits | |
Neidhardt et al. | Molecular cloning and expression of a gene that controls the high-temperature regulon of Escherichia coli | |
Supply et al. | Identification of novel intergenic repetitive units in a mycobacterial two‐component system operon | |
JP2944094B2 (en) | Method for integrating target gene into bacterial chromosome and bacterium obtained by the method | |
Ozenberger et al. | Nucleotide sequence of Escherichia coli isochorismate synthetase gene entC and evolutionary relationship of isochorismate synthetase and other chorismate-utilizing enzymes | |
Gawron-Burke et al. | Regeneration of insertionally inactivated streptococcal DNA fragments after excision of transposon Tn916 in Escherichia coli: strategy for targeting and cloning of genes from gram-positive bacteria | |
RU2072393C1 (en) | Method for obtaining recombination polypeptide possessing growth hormone properties | |
US20030032186A1 (en) | Method for stable chromosomal multi-copy integration of genes | |
Arps et al. | Structural analysis of the Escherichia coli K-12 hisT operon by using a kanamycin resistance cassette | |
Pettis et al. | Transcriptional mapping and nucleotide sequence of the Escherichia coli fepA-fes enterobactin region. Identification of a unique iron-regulated bidirectional promoter. | |
Curiale et al. | Intracistronic complementation of the tetracycline resistance membrane protein of Tn10 | |
Dougherty et al. | The Escherichia coli mutant requiring D-glutamic acid is the result of mutations in two distinct genetic loci | |
Ishiguro et al. | Nucleotide sequence of insertion sequence IS3411, which flanks the citrate utilization determinant of transposon Tn3411 | |
Ganduri et al. | TdcA, a transcriptional activator of the tdcABC operon of Escherichia coli, is a member of the LysR family of proteins | |
US4725535A (en) | Promoter probe vectors | |
Cirillo et al. | Genetic determination of the meso-diaminopimelate biosynthetic pathway of mycobacteria | |
CA2052324A1 (en) | Insertion of dna by modified transposons | |
US6248581B1 (en) | Mycobacteria functional screening and/or expression vectors | |
Frick et al. | Cloning of immunity and structural genes for colicin V | |
Rule et al. | Overproduction and nucleotide sequence of the respiratory D-lactate dehydrogenase of Escherichia coli | |
WO1995004830A1 (en) | Mycoplasma expression system | |
US5821059A (en) | Mycoplasma expression system | |
Conway et al. | Gene expression in Zymomonas mobilis: promoter structure and identification of membrane anchor sequences forming functional lacZ'fusion proteins | |
CN101305096B (en) | Novel selection system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2168866 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993918682 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08592406 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1993918682 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993918682 Country of ref document: EP |